+33(0)1 42 54 60 64 | contact@welcomeurope.com

Horizon 2020 – IMI II – Research and Innovation action – 2020

Funds for improving the drug development process by supporting more efficient research and development cooperation among academia, SMEs and the biopharmaceutical industry.

2020-05-12
273,218,500 million euro
Close

Appeal framework

Institution European Commission
Sectors Health
Beneficiaries
Regions European Union

Content reserved for subscribers

Register for free to access the content

Free access to all information

Priorities and funded actions

TOPICS

Open
– IMI-2020-20-01: Early diagnosis, prediction of radiographic outcomes and development of rational, personalised treatment strategies to improve long-term outcomes in psoriatic arthritis;
– IMI2-2020-20-02: Innovations to accelerate vaccine development vaccine development and manufacture;
– IMI2-2020-20-03: Academia and industry united innovation and treatment for tuberculosis (UNITE4TB);
– IMI2-2020-20-04: Tumour plasticity;
– IMI2-2020-20-05: Proton versus photon therapy for oesophageal cancer – a trimodality strategy;
– IMI2-2020-20-06: Handling of protein drug products and stability concerns

Financement

Test your eligibility

Other funds:

Aucune relation trouvée.

Similar news

25 August 2021

Webinar Horizon Europe: Guide to prepare an accurate financial statement on time

Read the article

9 June 2021

Welcomeurope’s new service!

Read the article